Posted by on November 16, 2020 11:28 am
Originally From: TowleRoad

Tags: , , , ,

Massachusetts-based biotech company Moderna announced on Monday morning that its vaccine is 94.5% effective in a study of more than 30,000 volunteers. The announcement comes one week after rival firm Pfizer announced a vaccine with 90 percent efficacy.

The company added: “The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001). A secondary endpoint analyzed severe cases of COVID-19 and included 11 severe cases (as defined in the

READ MORE OF THIS POST AT TowleRoad

Leave a Reply

Your email address will not be published. Required fields are marked *

Live Guys Online Now!
Live Guys Online Now!